Effect of CT fluoroscopy-guided transpulmonary radiofrequency ablation of liver tumours on the lung

T. Iguchi, D. Inoue, K. Yabushita, K. Sakaguchi, M. Tatsukawa, H. Sasaki, S. Kanazawa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: We retrospectively evaluated the effect of transpulmonary radiofrequency ablation (RFA) of liver tumours on the lung. Methods: 16 patients (10 males and 6 females; mean age, 65.2 years) with 16 liver tumours (mean diameter 1.5 cm) underwent transpulmonary RFA under CT fluoroscopic guidance. The tumours were either hepatocellular carcinoma (n=14) or liver metastasis (n=12). All 16 liver tumours were undetectable with ultrasonography. The pulmonary function values at 3 months after transpulmonary RFA were compared with baseline (i.e. values before RFA). Results: In 8 of 16 sessions, minor pulmonary complications occurred, including small pneumothorax (n=8) and small pleural effusion (n=1). In two sessions, major pulmonary complications occurred, including pneumothorax requiring a chest tube (n52). These chest tubes were removed at 4 and 6 days, and these patients were discharged 7 and 10 days after RFA, respectively, without any sequelae. The pulmonary function values we evaluated were forced expiratory volume in 1 s (FEV1.0) and vital capacity (VC). The mean values of FEV1.0 before and 3 months after RFA were 2.55 l and 2.59 l, respectively; the mean values of VC before and 3 months after RFA were 3.20 l and 3.27 l, respectively. These pulmonary values did not show any significant worsening (p=0.393 and 0.255 for FEV1.0 and VC, respectively). Conclusion: There was no significant lung injury causing a fatal or intractable complication after transpulmonary RFA of liver tumours.

Original languageEnglish
JournalBritish Journal of Radiology
Volume85
Issue number1016
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Fluoroscopy
Lung
Liver
Vital Capacity
Chest Tubes
Neoplasms
Pneumothorax
Forced Expiratory Volume
Lung Injury
Pleural Effusion
Hepatocellular Carcinoma
Ultrasonography
Neoplasm Metastasis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Effect of CT fluoroscopy-guided transpulmonary radiofrequency ablation of liver tumours on the lung. / Iguchi, T.; Inoue, D.; Yabushita, K.; Sakaguchi, K.; Tatsukawa, M.; Sasaki, H.; Kanazawa, S.

In: British Journal of Radiology, Vol. 85, No. 1016, 08.2012.

Research output: Contribution to journalArticle

Iguchi, T. ; Inoue, D. ; Yabushita, K. ; Sakaguchi, K. ; Tatsukawa, M. ; Sasaki, H. ; Kanazawa, S. / Effect of CT fluoroscopy-guided transpulmonary radiofrequency ablation of liver tumours on the lung. In: British Journal of Radiology. 2012 ; Vol. 85, No. 1016.
@article{8fdb271b214f42ed81e01d983c731945,
title = "Effect of CT fluoroscopy-guided transpulmonary radiofrequency ablation of liver tumours on the lung",
abstract = "Objective: We retrospectively evaluated the effect of transpulmonary radiofrequency ablation (RFA) of liver tumours on the lung. Methods: 16 patients (10 males and 6 females; mean age, 65.2 years) with 16 liver tumours (mean diameter 1.5 cm) underwent transpulmonary RFA under CT fluoroscopic guidance. The tumours were either hepatocellular carcinoma (n=14) or liver metastasis (n=12). All 16 liver tumours were undetectable with ultrasonography. The pulmonary function values at 3 months after transpulmonary RFA were compared with baseline (i.e. values before RFA). Results: In 8 of 16 sessions, minor pulmonary complications occurred, including small pneumothorax (n=8) and small pleural effusion (n=1). In two sessions, major pulmonary complications occurred, including pneumothorax requiring a chest tube (n52). These chest tubes were removed at 4 and 6 days, and these patients were discharged 7 and 10 days after RFA, respectively, without any sequelae. The pulmonary function values we evaluated were forced expiratory volume in 1 s (FEV1.0) and vital capacity (VC). The mean values of FEV1.0 before and 3 months after RFA were 2.55 l and 2.59 l, respectively; the mean values of VC before and 3 months after RFA were 3.20 l and 3.27 l, respectively. These pulmonary values did not show any significant worsening (p=0.393 and 0.255 for FEV1.0 and VC, respectively). Conclusion: There was no significant lung injury causing a fatal or intractable complication after transpulmonary RFA of liver tumours.",
author = "T. Iguchi and D. Inoue and K. Yabushita and K. Sakaguchi and M. Tatsukawa and H. Sasaki and S. Kanazawa",
year = "2012",
month = "8",
doi = "10.1259/bjr/34646739",
language = "English",
volume = "85",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "1016",

}

TY - JOUR

T1 - Effect of CT fluoroscopy-guided transpulmonary radiofrequency ablation of liver tumours on the lung

AU - Iguchi, T.

AU - Inoue, D.

AU - Yabushita, K.

AU - Sakaguchi, K.

AU - Tatsukawa, M.

AU - Sasaki, H.

AU - Kanazawa, S.

PY - 2012/8

Y1 - 2012/8

N2 - Objective: We retrospectively evaluated the effect of transpulmonary radiofrequency ablation (RFA) of liver tumours on the lung. Methods: 16 patients (10 males and 6 females; mean age, 65.2 years) with 16 liver tumours (mean diameter 1.5 cm) underwent transpulmonary RFA under CT fluoroscopic guidance. The tumours were either hepatocellular carcinoma (n=14) or liver metastasis (n=12). All 16 liver tumours were undetectable with ultrasonography. The pulmonary function values at 3 months after transpulmonary RFA were compared with baseline (i.e. values before RFA). Results: In 8 of 16 sessions, minor pulmonary complications occurred, including small pneumothorax (n=8) and small pleural effusion (n=1). In two sessions, major pulmonary complications occurred, including pneumothorax requiring a chest tube (n52). These chest tubes were removed at 4 and 6 days, and these patients were discharged 7 and 10 days after RFA, respectively, without any sequelae. The pulmonary function values we evaluated were forced expiratory volume in 1 s (FEV1.0) and vital capacity (VC). The mean values of FEV1.0 before and 3 months after RFA were 2.55 l and 2.59 l, respectively; the mean values of VC before and 3 months after RFA were 3.20 l and 3.27 l, respectively. These pulmonary values did not show any significant worsening (p=0.393 and 0.255 for FEV1.0 and VC, respectively). Conclusion: There was no significant lung injury causing a fatal or intractable complication after transpulmonary RFA of liver tumours.

AB - Objective: We retrospectively evaluated the effect of transpulmonary radiofrequency ablation (RFA) of liver tumours on the lung. Methods: 16 patients (10 males and 6 females; mean age, 65.2 years) with 16 liver tumours (mean diameter 1.5 cm) underwent transpulmonary RFA under CT fluoroscopic guidance. The tumours were either hepatocellular carcinoma (n=14) or liver metastasis (n=12). All 16 liver tumours were undetectable with ultrasonography. The pulmonary function values at 3 months after transpulmonary RFA were compared with baseline (i.e. values before RFA). Results: In 8 of 16 sessions, minor pulmonary complications occurred, including small pneumothorax (n=8) and small pleural effusion (n=1). In two sessions, major pulmonary complications occurred, including pneumothorax requiring a chest tube (n52). These chest tubes were removed at 4 and 6 days, and these patients were discharged 7 and 10 days after RFA, respectively, without any sequelae. The pulmonary function values we evaluated were forced expiratory volume in 1 s (FEV1.0) and vital capacity (VC). The mean values of FEV1.0 before and 3 months after RFA were 2.55 l and 2.59 l, respectively; the mean values of VC before and 3 months after RFA were 3.20 l and 3.27 l, respectively. These pulmonary values did not show any significant worsening (p=0.393 and 0.255 for FEV1.0 and VC, respectively). Conclusion: There was no significant lung injury causing a fatal or intractable complication after transpulmonary RFA of liver tumours.

UR - http://www.scopus.com/inward/record.url?scp=84864860896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864860896&partnerID=8YFLogxK

U2 - 10.1259/bjr/34646739

DO - 10.1259/bjr/34646739

M3 - Article

C2 - 22374277

AN - SCOPUS:84864860896

VL - 85

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 1016

ER -